During the corresponding time, Assembly Biosciences Inc recorded a revenue increase by 38.94 % year on year, sequentially revenue grew by 62.84 %. While revenue at the Assembly Biosciences Inc 's corporate clients
Assembly Biosciences Inc's Comment on Sales, Marketing and Customers
The company addresses regulatory and compliance challenges related to privacy, data security laws, FDA regulations, and emerging technologies, including artificial intelligence, with a focus on the European Union and United Kingdom markets.
In an era marked by significant advancements in antiviral therapy, Assembly Biosciences has unveiled pivotal data at the 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID) that could reshape our understanding and management of herpes simplex virus (HSV) infections. The spotlight was firmly placed on ABI-5366, a novel long-acting helicase-primase inhibitor candidate, whose clinical and preclinical trial data were showcased through two illuminating poster presentations.Genital herpes, predominantly caused by HSV type 2, represents a substantial public health challenge, affecting millions globally. Prevalence patterns reveal a troubling trajectory, with the incidence of new infecti...
Assembly Biosciences, a biotechnology company focused on developing therapeutics for serious viral diseases, has recently announced the initiation of a Phase 1b clinical trial evaluating their next-generation capsid assembly modulator candidate, ABI-4334, for the treatment of chronic hepatitis B virus (HBV) infection. This groundbreaking study aims to assess the safety, pharmacokinetic, and efficacy endpoints in participants with chronic HBV infection. Interim data from the trial is expected to be available by the end of 2024.Chronic HBV infection affects millions of individuals worldwide and can lead to serious health complications, including liver cirrhosis and hepatocellular carcinoma. Current treatment o...
Assembly Biosciences Outlines Anticipated Development Milestones for 2024; Strong Progress Expected for Clinical PipelineAssembly Biosciences, a renowned biotechnology company specializing in the development of innovative antiviral therapeutics targeting serious viral diseases, has unveiled its anticipated milestones and progress for its clinical pipeline during the year 2024. This announcement showcases the company s dedication to advancing the field of antiviral therapeutics and its commitment to addressing critical global health challenges.In a recent press release, Assembly Biosciences highlighted its key objectives for 2024, emphasizing its focus on clinical development. The company plans to advance mul...
Assembly Biosciences Inc’s Comment on Sales, Marketing and Customers
The company addresses regulatory and compliance challenges related to privacy, data security laws, FDA regulations, and emerging technologies, including artificial intelligence, with a focus on the European Union and United Kingdom markets.
Sources:
Assembly Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Assembly Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Assembly Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
